SLC5A2 and diabetes mellitus: The newer diabetes drug classes have also benefited from large recent clinical trials showing that SGLT‐2 inhibitors and GLP‐1 receptor agonists prevent major adverse cardiovascular events and progression of kidney disease.1, 2